ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Pharmacokinetics of Innovative versus Generic Valganciclovir in Kidney Transplant Recipients

I. Parra-Avila1, A. Cohen-Bucay1, J. Alberu2, G. Castañeda-Hernandez3, L. E. Morales-Buenrostro1

1Nephrology and Mineral Metabolism, Instituto Nacional de Ciencias Médicas y Nutrición, Ciudad de Mexico, Mexico, 2Transplant, Instituto Nacional de Ciencias Médicas y Nutrición, Ciudad de Mexico, Mexico, 3Pharmacology, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional, Ciudad de Mexico, Mexico

Meeting: 2019 American Transplant Congress

Abstract number: B239

Keywords: Cytomeglovirus, Kidney transplantation, Pharmacokinetics, Prophylaxis

Session Information

Date: Sunday, June 2, 2019

Session Name: Poster Session B: Kidney Infections

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Hall C & D

Related Abstracts
  • No Significant Outcome Benefit for Brand-Name Versus Generic Tacrolimus in Kidney Transplant Recipients: SRTR Analysis
  • Tacrolimus Dosing, Trough Concentrations and Dose Adjustments Compared Between Two Generic Formulations in Adult Kidney Transplant Recipients.

*Purpose: In kidney transplant recipients (KTR), cytomegalovirus (CMV) is a common viral infection associated with significant morbidity and mortality. In the absence of prophylaxis, CMV disease in high-risk recipients (D+/R-) has an incidence of 60%. Valganciclovir (VGCV) is commonly used for CMV prophylaxis. Generic VCGV is likely as effective as innovative VGCV and its use could be a safe strategy to reduce costs.Our aim was to compare pharmacokinetic parameters of innovative versus generic VGCV in KTR undergoing CMV prophylaxis with VGCV in the early post-transplant period.

*Methods: Crossover pharmacokinetic study in stable adult KTR undergoing prophylaxis with VGCV (900 mg daily), between days 31-90 post-transplant. All patients received both formulations (innovative and generic). At steady state (after 3 days), ganciclovir (GCV) blood concentration were measured at different times (0,0.5,1,2,4,8,12 and 24 h) and were determined by high performance liquid chromatography.

*Results: Eight adult KTR were included, age was 35.6 ± 9.8 years, 87.5% were males, body weight was 67.4 ± 13.7 kg, BSA was 1.7 ± 0.1m2, all received their first kidney-transplant, 62.5% were deceased donor recipients, eGFR using CKD-EPI was 82.2 ±20.3 ml/min/m2, 75% had (D+/R+) CMV serostatus, induction therapy with thymoglobulin was used in 75% of patients, all recipients were under maintenance immunosuppression with tacrolimus, MMF and steroids. A total of 64 samples were available for determining GCV plasma concentration (eight samples per patient). Pharmacokinetics was similar with both formulations for innovative and generic VGCV, figure.

*Conclusions: Pharmacokinetic studies in the early post-transplant period are needed to asses if bioavailability between innovative and generic formulation is similar, and concomitant drugs or unstable renal function can change drug plasma concentration. In the present study, both VGCV formulations provide similar GCV plasma concentration. Our study is limited by comparing only one generic formulation, and we cannot conclude that all generic VGCV formulations would behave similarly.

 border=

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Parra-Avila I, Cohen-Bucay A, Alberu J, Castañeda-Hernandez G, Morales-Buenrostro LE. Pharmacokinetics of Innovative versus Generic Valganciclovir in Kidney Transplant Recipients [abstract]. Am J Transplant. 2019; 19 (suppl 3). https://atcmeetingabstracts.com/abstract/pharmacokinetics-of-innovative-versus-generic-valganciclovir-in-kidney-transplant-recipients/. Accessed March 7, 2021.

« Back to 2019 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Home
  • Search
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.